<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="6073"><DrugName>zotepine</DrugName><DrugNamesKey><Name id="42769199">Lodopin</Name><Name id="42769200">Nipolept</Name><Name id="42769201">Zoleptil</Name><Name id="42757817">zotepine</Name></DrugNamesKey><DrugSynonyms><Name><Value>zotepine</Value><Types><Type>INN</Type></Types></Name><Name><Value>Lodopin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Nipolept</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Zoleptil</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>26615-21-4</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="16227">Fujisawa Pharmaceutical Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="17278">Italfarmaco SpA</Company><Company id="16247">Klinge Pharma GmbH</Company><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="25386">Knoll Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="6073" type="Drug"><TargetEntity id="91418" type="siDrug">Zotepine</TargetEntity></SourceEntity><SourceEntity id="16227" type="Company"><TargetEntity id="4295876872" type="organizationId">Fujisawa Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="16247" type="Company"><TargetEntity id="5035882106" type="organizationId">Klinge Pharma GmbH</TargetEntity></SourceEntity><SourceEntity id="17278" type="Company"><TargetEntity id="4296367507" type="organizationId">Italfarmaco SpA</TargetEntity></SourceEntity><SourceEntity id="25386" type="Company"><TargetEntity id="5000417813" type="organizationId">Knoll Ltd</TargetEntity></SourceEntity><SourceEntity id="25" type="ciIndication"><TargetEntity id="10057666" type="MEDDRA"/><TargetEntity id="D001008" type="MeSH"/><TargetEntity id="-1384065283" type="omicsDisease"/><TargetEntity id="30" type="siCondition"/></SourceEntity><SourceEntity id="282" type="ciIndication"><TargetEntity id="10061920" type="MEDDRA"/><TargetEntity id="D011618" type="MeSH"/><TargetEntity id="61" type="siCondition"/></SourceEntity><SourceEntity id="299" type="ciIndication"><TargetEntity id="F20" type="ICD10"/><TargetEntity id="10039626" type="MEDDRA"/><TargetEntity id="D012559" type="MeSH"/><TargetEntity id="-729613619" type="omicsDisease"/><TargetEntity id="65" type="siCondition"/></SourceEntity><SourceEntity id="145" type="Action"><TargetEntity id="123" type="Mechanism">Dopamine Receptor Antagonists</TargetEntity></SourceEntity><SourceEntity id="13" type="Action"><TargetEntity id="948" type="Mechanism">5-HT2 Antagonists</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Anxiety disorder - Japan - Mar-1995</FirstLaunched><FirstLaunched>Psychotic disorder - Austria - Mar-1995</FirstLaunched><FirstLaunched>Psychotic disorder - Germany - Mar-1995</FirstLaunched><FirstLaunched>Psychotic disorder - Japan - Mar-1995</FirstLaunched><FirstLaunched>Psychotic disorder - Switzerland - Mar-1995</FirstLaunched><FirstLaunched>Schizophrenia - Austria - Mar-1995</FirstLaunched><FirstLaunched>Schizophrenia - Germany - Mar-1995</FirstLaunched><FirstLaunched>Schizophrenia - Japan - Mar-1995</FirstLaunched><FirstLaunched>Schizophrenia - Switzerland - Mar-1995</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="25">Anxiety disorder</Indication><Indication id="282">Psychotic disorder</Indication><Indication id="299">Schizophrenia</Indication></IndicationsPrimary><ActionsPrimary><Action id="145">Dopamine receptor antagonist</Action><Action id="13">5-HT 2 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2943">Antipsychotic</Action><Action id="2942">Anxiolytic</Action></ActionsSecondary><Technologies><Technology id="603">Systemic formulation unspecified</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="744">Liquid-based formulation technology</Technology></Technologies><EphmraCodes><Ephmra><Code>N5A</Code><Name>ANTIPSYCHOTICS</Name></Ephmra><Ephmra><Code>N5C</Code><Name>TRANQUILLISERS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-03-29T16:59:00.000Z</LastModificationDate><ChangeDateLast>2017-03-29T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1013295" linkType="Company"&gt;Fujisawa&lt;/ulink&gt; (now &lt;ulink linkID="1013295" linkType="Company"&gt;Astellas Pharma&lt;/ulink&gt;) has developed and launched zotepine, a dopamine and 5-HT2 antagonist, for the treatment of psychosis, schizophrenia and anxiety disorders   [&lt;ulink linkID="190277" linkType="reference"&gt;190277&lt;/ulink&gt;], [&lt;ulink linkID="308687" linkType="reference"&gt;308687&lt;/ulink&gt;], [&lt;ulink linkID="592748" linkType="Reference"&gt;592748&lt;/ulink&gt;]. By 1998, &lt;ulink linkID="6073" linkType="Drug"&gt;zotepine&lt;/ulink&gt; had been launched in Austria, Japan, Switzerland, Germany and South Korea  [&lt;ulink linkID="190277" linkType="reference"&gt;190277&lt;/ulink&gt;], [&lt;ulink linkID="308687" linkType="reference"&gt;308687&lt;/ulink&gt;]. By March 2000, it was marketed in the UK as Zoleptil by &lt;ulink linkID="18693" linkType="Company"&gt;Orion&lt;/ulink&gt; [&lt;ulink linkID="402742" linkType="reference"&gt;402742&lt;/ulink&gt;]. In July 2000, the product was also launched in Taiwan [&lt;ulink linkID="379420" linkType="reference"&gt;379420&lt;/ulink&gt;]. In May 2007, the drug was launched by &lt;ulink linkID="17278" linkType="Company"&gt;Italfarmaco&lt;/ulink&gt;  in Portugal [&lt;ulink linkID="1389831" linkType="Reference"&gt;1389831&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Zotepine also has a high affinity for the 5-HT7 receptor, although the implications of this are unknown [&lt;ulink linkID="277196" linkType="reference"&gt;277196&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2017, &lt;ulink linkID="1145602" linkType="Company"&gt;LTL Pharma&lt;/ulink&gt; was to acquire marketing authorization of  Lodopin from Astellas and it would assume the supply of the drug to third parties in Japan and outside of Japan. The agreement was expected to close on April 28, 2017 and the transfer of the product was planned to be completed by April 2020 [&lt;ulink linkID="1912227" linkType="Reference"&gt;1912227&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="25386" linkType="Company"&gt;Knoll&lt;/ulink&gt; was previously developing the drug for the potential treatment of psychotic disorder and schizophrenia. By 1995, phase III trials had been ongoing in Western Europe  [&lt;ulink linkID="190277" linkType="reference"&gt;190277&lt;/ulink&gt;]. The company had planned to file for approval in the UK in 1996 [&lt;ulink linkID="216273" linkType="reference"&gt;216273&lt;/ulink&gt;]. However, no further development was reported from Knoll. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Knoll has marketing rights for zotepine in the US and Europe, except Austria and Germany. However, there has been no development of the compound reported in the US and, by February 2002, the product was still not launched in the country [&lt;ulink linkID="439283" linkType="reference"&gt;439283&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Knoll's patent application, WO-09939709, claims a liquid formulation of zotepine [&lt;ulink linkID="345723" linkType="reference"&gt;345723&lt;/ulink&gt;]. In May 2001, patent US-06239165 was assigned to Knoll by the USPTO for this liquid formulation [&lt;ulink linkID="439291" linkType="reference"&gt;439291&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;subtitle&gt;Professor Gavin P Reynolds, &lt;ulink linkType="Company" linkID="21194"&gt;University of Sheffield&lt;/ulink&gt;, UK&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;8 April 1998&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="6073"&gt;Zotepine&lt;/ulink&gt; is an antipsychotic drug presently available in Austria, Japan, Switzerland and Germany. It is currently undergoing clinical trials with the aim of a launch in other countries for the treatment of psychosis, schizophrenia and anxiety disorders. Along with several new antipsychotic drugs, it is considered to demonstrate a lower incidence of extrapyramidal side effects (EPS) than occurs with the older-established compounds, and thus is widely described as an "atypical" antipsychotic. It also reportedly has a beneficial effect on the negative symptoms of schizophrenia, which are less responsive to treatment with the classical antipsychotics.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="6073"&gt;Zotepine&lt;/ulink&gt; is a dibenzothiepine which has similarities in its tricyclic structure to the archetypal atypical antipsychotic, the dibenzodiazepine &lt;ulink linkType="Drug" linkID="44371"&gt;clozapine&lt;/ulink&gt;. Similar tricyclic structures are exhibited by two other new antipsychotics that have recently been released, &lt;ulink linkType="Drug" linkID="3317"&gt;quetiapine&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt;. Unlike these other three drugs, however, &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt; does not exhibit the piperazinyl substituent on the middle ring but has an amino-substituted ethoxy group.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="6073"&gt;Zotepine&lt;/ulink&gt; is described as broad spectrum antipsychotic and is a 5-HT2/D2 antagonist, with a &lt;ulink linkType="Drug" linkID="4236"&gt;risperidone&lt;/ulink&gt;-like 5- to 10-fold higher affinity for the 5HT2A site over D2 receptors. It shares various aspects of its pharmacology with several other "atypical" antipsychotics that have recently been, or are about to be, released [&lt;ulink linkType="reference" linkID="255875"&gt;255875&lt;/ulink&gt;], although the mechanisms underlying this atypicality remain elusive [&lt;ulink linkType="reference" linkID="267684"&gt;267684&lt;/ulink&gt;]. A recent study has looked at the in vitro and in vivo receptor binding of several antipsychotic drugs, including &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt; among 11 established, recently released or developmental drugs [&lt;ulink linkType="reference" linkID="210677"&gt;210677&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="6073"&gt;Zotepine&lt;/ulink&gt; demonstrated an affinity higher than for the D2 receptor at the following sites: 5-HT2A, 5-HT2C, 5-HT7, alpha1 and histamine H1 receptors. This profile bears some resemblance to &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt;, although the latter shows a muscarinic antagonism but has a relatively weaker alpha1 effect. &lt;ulink linkType="Drug" linkID="6073"&gt;Zotepine&lt;/ulink&gt; has not got an equivalently high affinity at any of the five muscarinic acetylcholine receptor subtypes [&lt;ulink linkType="reference" linkID="21116"&gt;21116&lt;/ulink&gt;], nor does it share &lt;ulink linkType="Drug" linkID="44371"&gt;clozapine&lt;/ulink&gt;'s selectivity for the m1 subtype. &lt;ulink linkType="Drug" linkID="6073"&gt;Zotepine&lt;/ulink&gt;'s action at alpha1 and histamine H1 receptors presumably underlies its sedative effects, while it has been suggested that a 5-HT2C blockade may contribute to weight gain [&lt;ulink linkType="reference" linkID="255875"&gt;255875&lt;/ulink&gt;], a side effect of &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt; treatment (see below). The effects at 5-HT6 and 5-HT7 receptors have been proposed to be potentially important in mediating "atypicality", although a wide range of psychoactive compounds, including the classical antipsychotic chlorpromazine, also have effects at these sites [&lt;ulink linkType="reference" linkID="161010"&gt;161010&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug shows no particular selectivity for any of the dopamine D2-like receptors, with similar affinities (pKi ~ 10 nM) for the long and short forms of the D2 receptor and the D3 receptor, but a somewhat lower affinity at the D4 site [&lt;ulink linkType="reference" linkID="210677"&gt;210677&lt;/ulink&gt;]. These authors report a lower affinity too for the &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt; at the D1 site, although other reports suggest that its affinities at the human D1 and D2 receptors are very similar [&lt;ulink linkType="reference" linkID="275451"&gt;275451&lt;/ulink&gt;] and that this combined action may contribute to its reduced EPS profile.&lt;/para&gt;&lt;para&gt;The in vivo pharmacology of &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt; confirms the drug's efficacy at 5-HT2 receptors, but also shows an alpha2-adrenergic antagonism equivalent to that of &lt;ulink linkType="Drug" linkID="4236"&gt;risperidone&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="124291"&gt;124291&lt;/ulink&gt;], which is only consistent with its reported affinity for the alpha2B receptor subtype [&lt;ulink linkType="reference" linkID="210677"&gt;210677&lt;/ulink&gt;]. In vivo effects mediated via 5-HT2C receptor antagonism are also apparent [&lt;ulink linkType="reference" linkID="200637"&gt;200637&lt;/ulink&gt;]. Surprisingly, one receptor occupancy study in rat brain showed that &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt; binds to dopamine D2 receptors without a substantial effect on dopamine D1 or 5-HT2 sites [&lt;ulink linkType="reference" linkID="185676"&gt;185676&lt;/ulink&gt;], although these results are not consistent with those from quantitative autoradiography [&lt;ulink linkType="reference" linkID="210677"&gt;210677&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;The effect of single oral doses of &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt; on blood concentrations and pharmacodynamics in healthy subjects has been examined [&lt;ulink linkType="reference" linkID="200756"&gt;200756&lt;/ulink&gt;]. Plasma concentrations peaked at 2 to 4 h after dosing. However more recent metabolic studies indicate later peak times and a second peak 10 to 12 h after administration, with a correspondingly long elimination half-life [&lt;ulink linkType="reference" linkID="275443"&gt;275443&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Smoking has no apparent effect on the pharmacokinetics of &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt;, nor does the status of CYP2C19 metabolism. However, coadministration of diazepam increases &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt; plasma levels, presumably by inhibition of other metabolic mechanisms [&lt;ulink linkType="reference" linkID="275442"&gt;275442&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The initial desmethyl metabolite of &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt;, norzotepine, is present in plasma at concentrations up to 25% of those of zotepine. Although weaker in its effects than the parent drug, norzotepine has a greater &lt;ulink linkType="Drug" linkID="44371"&gt;clozapine&lt;/ulink&gt;-like selectivity for limbic components of amphetamine-induced behaviors and thus has been suggested to contribute to clinical efficacy [&lt;ulink linkType="reference" linkID="275447"&gt;275447&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="6073"&gt;Zotepine&lt;/ulink&gt; is available in several countries and is in advanced clinical trials in others. It is well established as having antipsychotic efficacy in double-blind trials against haloperidol and perazine, with indications of a fairly rapid onset of action; BPRS scores improving significantly within 2 weeks [eg, 200762, 200765, 275452]. Some early open studies indicated efficacy of the drug against negative symptoms, and this has been confirmed in double-blind comparison with haloperidol [&lt;ulink linkType="reference" linkID="200661"&gt;200661&lt;/ulink&gt;]. However, it has been suggested that evidence is lacking for effects of the drug on primary negative symptomatology, distinct from changes secondary to either improvements in positive symptoms or diminished parkinsonian symptoms [&lt;ulink linkType="reference" linkID="275436"&gt;275436&lt;/ulink&gt;]. In some double-blind tests of the effects of &lt;ulink linkType="Drug" linkID="44371"&gt;clozapine&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt; on cognitive function in schizophrenic subjects, &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt; was able to demonstrate an improvement that was greater than the effect of &lt;ulink linkType="Drug" linkID="44371"&gt;clozapine&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="275441"&gt;275441&lt;/ulink&gt;], which is itself established as having beneficial effects on cognition.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side-effects and Contraindications&lt;/subtitle&gt;One major advantage of &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt; over the classical antipsychotics is its low propensity to induce EPS. This conclusion has been drawn from studies including a double-blind comparison with relatively high doses of haloperidol, hardly the most discriminating of tests [&lt;ulink linkType="reference" linkID="275452"&gt;275452&lt;/ulink&gt;]; EPS was still reported in 5 of 26 patients receiving &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt;, although they had a notable absence of akathisia.&lt;br/&gt; &lt;br/&gt;In common with several other antipsychotics including &lt;ulink linkType="Drug" linkID="44371"&gt;clozapine&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt; induces a substantial weight gain, with a mean increases of 2.3 kg [&lt;ulink linkType="reference" linkID="275452"&gt;275452&lt;/ulink&gt;] and 3.6kg being recorded [&lt;ulink linkType="reference" linkID="275446"&gt;275446&lt;/ulink&gt;]. Other side effects of &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt; treatment are insomnia (also reported in the haloperidol comparison group) and hypouricaemia [&lt;ulink linkType="reference" linkID="275452"&gt;275452&lt;/ulink&gt;], although no clinical consequence of this latter observation is known. There is a report of a relatively high incidence of seizures following &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt; treatment; younger patients and those with a history of head-injury being particularly susceptible [&lt;ulink linkType="reference" linkID="200658"&gt;200658&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Some of the atypical antipsychotics, notably &lt;ulink linkType="Drug" linkID="44371"&gt;clozapine&lt;/ulink&gt;, have been found useful in the adjunctive treatment of Parkinson's disease, particularly in the amelioration of l-Dopa induced psychosis. &lt;ulink linkType="Drug" linkID="6073"&gt;Zotepine&lt;/ulink&gt; is unlikely to prove useful in this respect; it has been found that the drug can induce akinesia and rigidity in such patients [&lt;ulink linkType="reference" linkID="200558"&gt;200558&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Elevation of serum prolactin has been reported following &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt; treatment [&lt;ulink linkType="reference" linkID="200561"&gt;200561&lt;/ulink&gt;] and this has been correlated with clinical response but not with neurological side effects [&lt;ulink linkType="reference" linkID="200563"&gt;200563&lt;/ulink&gt;], emphasising the role of D2 receptor blockade (which mediates pituitary secretion of prolactin) in the therapeutic effects of the drug.&lt;br/&gt;Some recent studies have emphasised the value of subjective patient assessment of the impact of antipsychotic drug treatment on quality of life. An open comparison of &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="44371"&gt;clozapine&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="4236"&gt;risperidone&lt;/ulink&gt; and conventional antipsychotics found patients on &lt;ulink linkType="Drug" linkID="44371"&gt;clozapine&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="4236"&gt;risperidone&lt;/ulink&gt; to rate quality of life higher than those on &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt; or the conventional antipsychotics [&lt;ulink linkType="reference" linkID="283567"&gt;283567&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;There is no doubt that &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt; is an effective antipsychotic drug and that there is some evidence that this efficacy is faster in onset. The notable and rapid improvement reported in negative symptoms scores is potentially valuable, although it is not yet clear how well such measures are reflections of primary negative symptomatology. There is increasing recognition of the importance of cognitive deficits in the clinical profile of schizophrenia; the effect of &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt; on cognition is particularly interesting in this respect.&lt;/para&gt;&lt;para&gt;It is likely that the reported relative reduction in quality of life reflects some of the side-effects of the drug. Thus EPS and the requirement for concurrent antiparkinsonian medication is found in a proportion of &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt;-treated patients. Weight gain too is a substantial side effect, although this is also a major problem with several other antipsychotics, notably including &lt;ulink linkType="Drug" linkID="44371"&gt;clozapine&lt;/ulink&gt; and the recently released &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt;. Weight gain may reflect 5-HT2C antagonism, while EPS is a function of D2 receptor blockade and indicates fairly high occupancy of this receptor, in contrast to the lower occupancy in human brain observed with two of the atypical antipsychotics, &lt;ulink linkType="Drug" linkID="44371"&gt;clozapine&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3317"&gt;quetiapine&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="283569"&gt;283569&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Thus while &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt; is an effective and fast-acting antipsychotic with effects on negative and cognitive symptoms and a diminished incidence of EPS, it is unclear whether the drug will offer any substantial advantage over some of its recently-introduced competitors which include &lt;ulink linkType="Drug" linkID="3317"&gt;quetiapine&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt;. One indication that is yet untested is &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt;'s effect in patients who are otherwise treatment-resistant. So far there is no clear challenger to &lt;ulink linkType="Drug" linkID="44371"&gt;clozapine&lt;/ulink&gt;'s unique efficacy in this sub-group of patients; a role for &lt;ulink linkType="Drug" linkID="6073"&gt;zotepine&lt;/ulink&gt; here would be invaluable.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="282">Psychotic disorder</Indication><StatusDate>1998-12-01T00:00:00.000Z</StatusDate><Source id="308687" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="282">Psychotic disorder</Indication><StatusDate>1995-03-01T00:00:00.000Z</StatusDate><Source id="190277" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication><StatusDate>1995-03-01T00:00:00.000Z</StatusDate><Source id="190277" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16247">Klinge Pharma GmbH</Company><Country id="AT">Austria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate>1995-03-01T00:00:00.000Z</StatusDate><Source id="190277" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16247">Klinge Pharma GmbH</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="282">Psychotic disorder</Indication><StatusDate>1995-03-01T00:00:00.000Z</StatusDate><Source id="190277" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16247">Klinge Pharma GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="282">Psychotic disorder</Indication><StatusDate>1995-03-01T00:00:00.000Z</StatusDate><Source id="190277" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16247">Klinge Pharma GmbH</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate>1995-03-01T00:00:00.000Z</StatusDate><Source id="190277" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate>2000-07-01T00:00:00.000Z</StatusDate><Source id="379420" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="282">Psychotic disorder</Indication><StatusDate>2000-07-01T00:00:00.000Z</StatusDate><Source id="379420" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate>1995-03-01T00:00:00.000Z</StatusDate><Source id="190277" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17278">Italfarmaco SpA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate>2007-05-11T00:00:00.000Z</StatusDate><Source id="1389831" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication><StatusDate>2000-07-01T00:00:00.000Z</StatusDate><Source id="379420" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate>1998-12-01T00:00:00.000Z</StatusDate><Source id="308687" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16247">Klinge Pharma GmbH</Company><Country id="AT">Austria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="282">Psychotic disorder</Indication><StatusDate>1995-03-01T00:00:00.000Z</StatusDate><Source id="190277" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16247">Klinge Pharma GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate>1995-03-01T00:00:00.000Z</StatusDate><Source id="190277" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25386">Knoll Ltd</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="282">Psychotic disorder</Indication><StatusDate>1996-08-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25386">Knoll Ltd</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate>1996-08-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25386">Knoll Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="282">Psychotic disorder</Indication><StatusDate>1996-08-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25386">Knoll Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate>1996-08-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="25386">Knoll Ltd</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate>1995-03-01T00:00:00.000Z</StatusDate><Source id="190277" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25386">Knoll Ltd</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="282">Psychotic disorder</Indication><StatusDate>1995-03-01T00:00:00.000Z</StatusDate><Source id="190277" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25386">Knoll Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate>1995-03-01T00:00:00.000Z</StatusDate><Source id="172924" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25386">Knoll Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="282">Psychotic disorder</Indication><StatusDate>1995-03-01T00:00:00.000Z</StatusDate><Source id="172924" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16247">Klinge Pharma GmbH</Company><Country id="AT">Austria</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="282">Psychotic disorder</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16247">Klinge Pharma GmbH</Company><Country id="AT">Austria</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="299">Schizophrenia</Indication></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00018"><Name>5-HT 2 receptor</Name><SwissprotNumbers/></Target><Target id="PTGT-00637"><Name>Dopamine receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1013295">Astellas Pharma Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="1145602">LTL Pharma Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="13601">Abbott Laboratories</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17278">Italfarmaco SpA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18693">Orion Corp</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>3</CountActive><CountInactive>0</CountInactive><CountTotal>3</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CN(C)CCOC1=Cc2ccccc2Sc3c1cc(cc3)Cl</Smiles></StructureSmiles><Deals><Deal id="120197" title="Orion to market Fujisawa's zotepine in the UK"/><Deal id="120202" title="Knoll to market Fujisawa's zotepine in US and Europe, excluding Austria and Germany"/><Deal id="145495" title="Italfarmaco to commercialize Fujisawa Pharmaceutical's zotepine in Portugal "/><Deal id="237522" title="LTL Pharma acquires Astellas pharma's products in Japan"/></Deals><PatentFamilies><PatentFamily id="1502998" number="WO-09939709" title="Liquid pharmaceutical formulation containing zotepine."/><PatentFamily id="314224" number="US-03704245" title="Tricyclic enol ether compounds."/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Astellas Pharma Inc" id="1013295"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bionevia Pharmaceuticals Inc" id="1048711"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Parul Group of Institutes" id="1103739"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Abbott Laboratories" id="13601"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eli Lilly &amp; Co" id="17810"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>